CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Omthera Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Omthera Pharmaceuticals Inc
707 State Road
Phone: (908) 741-4399p:908 741-4399 PRINCETON, NJ  08540  United States Ticker: OMTHOMTH
This company was Merged or Acquired on 7/18/2013.
This company ceased filing statements with the SEC on 7/29/2013.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Omthera Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, its product candidate, is a late-stage, omega-three free fatty acid composition that reduces triglycerides, improves other key lipid parameters. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-three and omega-six fatty acids, with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid being the most abundant forms of omega-three fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201212/31/2012YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8733 Noncommercial research organizations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board George F.Horner 65 4/1/2010
President, Chief Executive Officer, Co-Founder, Director Gerald L.Wisler 56 12/1/2008
Chief Financial Officer, Executive Vice President Christian S.Schade 52 9/1/2011 9/1/2011
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 14 (As of 12/31/2012)
Outstanding Shares: 21,121,044 (As of 4/1/2013)
Stock Exchange: NASD
Federal Tax Id: 263797738
Fax Number: (908) 741-6524


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023